MONITORING THE CELLULAR COMPONENTS OF THE IMMUNE SYSTEM DURING CLINICAL TRIALS: A TRANSLATIONAL MEDICINE APPROACH - Flow Cytometry in Drug Discovery and Development - page 196

CTL cytotoxic T lymphocyte

DC dendritic cell

DN double negative

HIV human immunode ciency virus

IFN- g interferon gamma

Ig immunoglobulin

IL interleukin

LFA leukocyte function antigen

mAb monoclonal antibody

NIH National Institutes of Health

NK natural killer cell

PD pharmacodynamics

PK pharmacokinetics

RA rheumatoid arthritis

SLE systemic lupus erythratomas

TCR T-cell receptor

Th T-helper cell

Treg regulatory T cell

TLR Toll-like receptor

ACKNOWLEDGMENT

The authors thank Mr. Viq Pervaaz and Dr. Sophie Connetable for critical review of
this chapter.

REFERENCES

1. Lean MEJ, Mann JI, Hoek JA, Elliot RM, Schofield G. Translational research: from
evidence-based medicine to sustainable solutions for public health problems. Br. Med. J.
2008;337:a863.
2. ( http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp)
3. Carpenter S. Carving a career in translational research. Science 2007;317(5840):966-967.
4. Feuerstein GZ, Rutkowski JL, Walsh FS, Stiles GL, Ruffolo RR, Jr., The role of
translational medicine and biomarker research in drug discovery and development.
Am. Drug Discov. 2007;2(1):23-28.
5. Atkinson AJ, Jr., Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates
JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. Biomarkers and surrogate
endpoints: preferred definitions and conceptual framework. Biomarkers Definitions
Working Group. Clin. Pharmacol. Ther. 2001;69:89-95.
6. Wan HI, Day M, Hurko O, Rutowski JL. Biomarkers for Alzheimer's disease: translation
medicine approaches in development of disease modifying therapeutic. Am. Pharmaceut.
Rev. 2008;11:83-92.
7. Vesterqvist OE, Park CH, Rutkowski JL. From biological measures to valid biomarker:
predicting success of novel therapeutic. Am. Drug. Discov. 2007;3(3):56-59.